Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial

1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2016;382:209–22.

2. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62:S96–105. doi: 10.1093/cid/civ1013 27059362

3. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec. 2006;81:2–11.

4. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;376:606–14.

5. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–98. doi: 10.1056/NEJMoa0904797 20107214

6. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:615–23. doi: 10.1016/S0140-6736(10)60755-6 20692031

7. World Health Organization. Rotavirus vaccines WHO position paper—January 2013. Wkly Epidemiol Rec. 2013;88:49–64. 23424730

8. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27:1333–9. doi: 10.1016/j.vaccine.2008.12.059 19162114

9. Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008;27:874–80. doi: 10.1097/INF.0b013e3181782780 18756184

10. Neuzil KM, Zaman K, Victor JC. A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. Vaccine. 2014;32(Suppl 1):A179–84.

11. Rotavirus vaccines: an update. Wkly Epidemiol Rec. 2009;84:533–40. 20034143

12. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;383:2136–43.

13. Halloran ME, Longini IMJ, Struchiner CJ. Design and analysis of vaccine studies. 1st ed. New York: Springer-Verlag; 2010.

14. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children’s Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol. 2009;16:382–6. doi: 10.1128/CVI.00382-08 19158283

15. Gastanaduy PA, Curns AT, Parashar UD, Lopman BA. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. JAMA. 2013;310:851–3. doi: 10.1001/jama.2013.170800 23982372

16. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204:980–6. doi: 10.1093/infdis/jir492 21878425

17. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine. 2012;30:552–64. doi: 10.1016/j.vaccine.2011.11.064 22133508

18. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30:S25–9. doi: 10.1097/INF.0b013e3181fefdee 21183837

19. International Centre for Diarrhoeal Disease Research, Bangladesh. Health and Demographic Surveillance System—Matlab. Registration of health and demographic events 2010. Dhaka: International Centre for Diarrhoeal Disease Research, Bangladesh; 2012.

20. Government of People’s Republic of Bangladesh. Comprehensive multi-year plan of the National Immunization Program of Bangladesh 2011–2016. Geneva: Gavi, the Vaccine Alliance; 2011 [cited 2017 Feb 3]. Available from: http://www.gavi.org/country/bangladesh/documents/cmyps/comprehensive-multi-year-plan-for-2011-2016/. Accessed 3 February 2017.

21. Hayes RJ, Moulton LH. Cluster randomised trials. Boca Raton: Chapman &Hall/CRC Taylor & Francis Group; 2009.

22. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22:259–67. doi: 10.3109/00365549009027046 2371542

23. Rahman M, Sultana R, Ahmed G, Nahar S, Hassan ZM, Saiada F, et al. Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh. Emerg Infect Dis. 2007;13:18–24. doi: 10.3201/eid1301.060910 17370511

24. Begum YA, Baby NI, Faruque ASG, Jahan N, Cravioto A, Svennerholm A-M, et al. Shift in phenotypic characteristics of enterotoxigenic Escherichia coli (ETEC) isolated from diarrheal patients in Bangladesh. PLoS Negl Trop Dis. 2014;8:e3031. doi: 10.1371/journal.pntd.0003031 25032802

25. Blackwelder WC. Sample size and power for prospective analysis of relative risk. Stat Med. 1993;12:691–8. 8511445

26. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods. 1998;27:1305–22.

27. Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol. 2006;35:1292–300. doi: 10.1093/ije/dyl129 16943232

28. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. Boca Raton: Chapman & Hall/CRC Taylor & Francis Group; 1989.

29. Leshem E, Lopman B, Glass R, Gentsch J, Bányai K, Parashar U, et al. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis. 2016;14:847–56.

30. Afrad MH, Hassan Z, Farjana S, Moni S, Barua S, Das SK, et al. Changing profile of rotavirus genotypes in Bangladesh, 2006–2012. BMC Infect Dis. 2013;13:1–7.

31. Zaman K, Yunus M, Faruque ASG, Arifeen S El, Hossain I, Azim T, et al. Surveillance of rotavirus in a rural diarrhoea treatment centre in Bangladesh, 2000–2006. Vaccine. 2009;27(Suppl):F31–4.

32. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009;361:335–44. doi: 10.1056/NEJMoa0807521 19625715

33. Qadri F, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2016;386:1362–71.

34. Pringle KD, Patzi M, Tate JE, Iniguez Rojas V, Patel M, Inchauste Jordan L, et al. Sustained effectiveness of rotavirus vaccine against very severe rotavirus disease through the second year of life, Bolivia 2013–2014. Clin Infect Dis. 2016;62:S115–20. doi: 10.1093/cid/civ1026 27059344

35. Gastañaduy PA, Contreras-Roldán I, Bernart C, López B, Benoit SR, Xuya M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccines in Guatemala. Clin Infect Dis. 2016;62:S121–6. doi: 10.1093/cid/civ1208 27059345

36. Gheorghita S, Birca L, Donos A, Wasley A, Birca I, Cojocaru R, et al. Impact of rotavirus vaccine introduction and vaccine effectiveness in the Republic of Moldova. Clin Infect Dis. 2016;62:S140–6. doi: 10.1093/cid/civ1209 27059348

37. Sahakyan G, Grigoryan S, Wasley A, Mosina L, Sargsyan S, Asoyan A, et al. Impact and effectiveness of monovalent rotavirus vaccine in Armenian children. Clin Infect Dis. 2016;62:S147–54. doi: 10.1093/cid/ciw045 27059349

38. Leshem E, Givon-Lavi N, Tate JE, Greenberg D, Parashar UD, Dagan R. Real-world effectiveness of pentavalent rotavirus vaccine among Bedouin and Jewish children in southern Israel. Clin Infect Dis. 2016;62:S155–60. doi: 10.1093/cid/civ1012 27059350

39. Gastañaduy PA, Steenhoff AP, Mokomane M, Esona MD, Bowen MD, Jibril H, et al. Effectiveness of monovalent rotavirus vaccine after programmatic implementation in Botswana: a multisite prospective case-control study. Clin Infect Dis. 2016;62:S161–7. doi: 10.1093/cid/civ1207 27059351

40. Armah G, Pringle K, Enweronu-Laryea CC, Ansong D, Mwenda JM, Diamenu SK, et al. Impact and effectiveness of monovalent rotavirus vaccine against severe rotavirus diarrhea in Ghana. Clin Infect Dis. 2016;62:S200–7. doi: 10.1093/cid/ciw014 27059357

41. Tate JE, Ngabo F, Donnen P, Gatera M, Uwimana J, Rugambwa C, et al. Effectiveness of pentavalent rotavirus vaccine under conditions of routine use in Rwanda. Clin Infect Dis. 2016;62:S208–12. doi: 10.1093/cid/civ1016 27059358

42. Bar-Zeev N, Jere KC, Bennett A, Pollock L, Tate JE, Nakagomi O, et al. Population impact and effectiveness of monovalent rotavirus vaccination in urban Malawian children 3 years after vaccine introduction: ecological and case-control analyses. Clin Infect Dis. 2016;62:S213–9. doi: 10.1093/cid/civ1183 27059359

43. Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis. 2016;14:1096–104.

44. Patel M, Pedreira C, De Oliveira LH, Umana J, Tate J, Lopman B, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. Pediatrics. 2012;130:e365–72. doi: 10.1542/peds.2011-3478 22753550

45. de Palma O, Cruz L, Ramos H, de Baires A, Villatoro N, Pastor D, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010;340:c2825. doi: 10.1136/bmj.c2825 20551120

46. Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, et al. Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012–2013. Clin Infect Dis. 2015;61:1792–9. doi: 10.1093/cid/civ872 26449565